Women’s Health Market, Analysis and Forecast - SITE LICENSE

The world population is constantly increasing & was estimated to be approximately 7.5 billion in April 2017. Women accounted for 49.6% of the total world population. They form an important part of the society and hence, the concerns regarding women’s health are pivotal for the overall well-being of the society. Women have higher life expectancy than men but a longer life does not ensure a healthy life.

Women health has long been a neglected issue, worldwide. Women undergo several biological, physical & psychological changes during their lifetime. These reoccurring changes, along with ageing, consequently lead to several health issues and related problems. The world population is ageing faster and women accounted for 54% of the population belonging to the age group of 60 years or over, in 2015. This percentage is expected to increase in the coming years. The different health issues that women face include infertility, hormonal changes, postmenopausal disorders and urinary infections, among others. The use of contraceptives by women is another issue that needs to be addressed. The market analysis includes an in-depth examination of the key ecosystem players and the key strategies & developments taking place in this market. Additionally, it includes the market dynamics (market drivers, opportunities and challenges) and industry analysis.
The purpose of the study is to gain a holistic view of the women’s health market in terms of the various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the women’s health market. The market has been segmented into ‘application’, ‘product’ and ‘geographical regions’. The report presents the reader with an opportunity to unlock the comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global women’s health market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global women’s health market and assesses the factors governing the same.
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges and opportunities in the global women’s health market?
• How did the women’s health market evolve in the past and what is its scope in the future?
• What is the market share of the leading segments and sub-segments of the global women’s health market in 2016 and 2023?
• How will each segment of the global women’s health market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016- 2023?
• What are the key developmental strategies that are being implemented by the key players to stand out in this market?
• How the market has been segmented on the basis of application?
• What are the treatment options for postmenopausal symptoms?
• What is the estimated value for menopausal hot flash market?
• What is the value of different types of contraceptives in the market?
• What will be the value of hormonal contraceptives segment by 2023?
• Which geographical location will contribute to the highest sales of the products?
The key players which have been significantly contributing to the Women’s health market are Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE, among others.
Executive Summary
1 Report Scope
1.1 Scope of the Report
1.2 Global Women's Health Market Segmentation
1.3 Key Learnings
1.4 Research Methodology
1.4.1. Data Triangulation
1.4.2. Key Data Points From Secondary Sources
1.4.3. Key Data Points From Primary Sources
1.4.4. Top-Down Approach (Segmental Analysis)
1.4.5. Bottom-Up Approach (Segmental Analysis)
1.4.6. Assumptions and Limitations
1.4.7. Data and Prediction Modelling
2 Market Overview
2.1 Introduction
3 Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
4 Competitive Insights
4.1. Share of Key Developments & Strategies
4.1.1. Collaborations/ Partnerships/ Joint Ventures/ Licensing Agreements
4.1.2. Regulatory Approvals
4.1.3. Mergers and Acquisitions
4.1.4. Business Expansions and Product Acquisitions
4.1.5. Product Launches
4.1.6. Others
5 Industry Insights
5.1. Regulatory Scenario
5.2. Patent Landscape
6 Global Women's Health Market, by Application
6.1. Segmentation of Global Women's Health Market, by Application
6.2. Reproductive Health
6.2.1. Infertility
6.2.2. Endometriosis
6.2.3. Poly Cystic Ovarian Syndrome (PCOS)
6.2.4. Contraceptives
6.2.4.1. Method of Contraceptive And Effectiveness
6.2.4.2. Types of Contraceptives
6.3. Post Menopausal Health
6.3.1. Menopause
6.3.2. Post Menopausal Osteoporosis
6.4. Urological Disorders
6.4.1. Urinary Incontinence
6.4.2. Urinary Tract Infection
6.4.3. Others
7 Global Women's Health Market, by Product Type
7.1. Introduction
7.2. Devices
7.2.1. Intra Uterine Devices
7.2.2. Vaginal Rings
7.2.3 Implants
7.2.4. Female Condoms
7.3. Drugs
7.3.1. Drugs for Treatment of Menopause
7.3.2. Drugs for Treatment of Menopausal Hot Flashes
7.4. Pharmaceutical Pipeline
8 Global Women's Health Market, by Geography
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9 Company Profiles
9.1. Abbott Laboratories
9.1.1. Overview
9.1.2. Abbott Laboratories: Product Portfolio
9.1.3. Financials
9.1.3.1. Financial Summary
9.1.4. Abbott Laboratories: SWOT Analysis
9.2. Agile THERAPEUTICS
9.2.1. Overview
9.2.2. Agile THERAPEUTICS: Product Portfolio
9.2.3. Financials
9.2.3.1. Financial Summary
9.2.4. Agile THERAPEUTICS: SWOT Analysis
9.3. Allergan plc.
9.3.1. Overview
9.3.2. Allergan plc: Product Portfolio
9.3.3. Financials
9.3.4. Allergan plc.: SWOT Analysis
9.4. Amgen Inc.
9.4.1. Overview
9.4.2. Amgen Inc.: Product Portfolio
9.4.3. Financials
9.4.3.1 Financial Summary
9.4.4. Amgen Inc.: SWOT Analysis
9.5. AstraZeneca PLC
9.5.1. Overview
9.5.2 AstraZeneca PLC: Product Portfolio
9.5.3. Financials
9.5.3.1. Financial Summary
9.5.4. AstraZeneca PLC: SWOT Analysis
9.6. Bayer AG
9.6.1. Overview
9.6.2. Bayer AG: Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. Bayer AG: SWOT Analysis
9.7. Eli Lilly and Company
9.7.1. Overview
9.7.2. Eli Lilly and Company: Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. Eli Lilly and Company: SWOT Analysis
9.8. Enteris BIOPHARMA, Inc
9.8.1. Overview
9.8.2. Enteris BIOPHARMA, Inc: Product Portfolio
9.8.3. Corporate Summary
9.8.4. Enteris BIOPHARMA, Inc: SWOT Analysis
9.9. Evestra, Inc
9.9.1. Overview
9.9.2. Evestra, Inc: Product Portfolio
9.9.3. Corporate Summary
9.9.4. Evestra, Inc: SWOT Analysis
9.10. FERRING PHARMACEUTICALS
9.10.1. Overview
9.10.2. FERRING PHARMACEUTICALS: Product Portfolio
9.10.3. Corporate Summary
9.10.4. FERRING PHARMACEUTICALS: SWOT Analysis
9.11. GEDEON RICHTER PLC
9.11.1. Overview
9.11.2. GEDEON RICHTER PLC: Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. GEDEON RICHTER PLC: SWOT Analysis
9.12. GlaxoSmithKline Plc
9.12.1. Overview
9.12.2. Glaxo: Product Portfolio
9.12.3. Financials
9.12.3.1. Financial Summary
9.12.4. GlaxoSmithKline Plc: SWOT Analysis
9.13. HRA Pharma
9.13.1. Overview
9.13.2. HRA Pharma: Product Portfolio
9.13.3. Corporate Summary
9.13.4. HRA Pharma: SWOT Analysis
9.14. JDS THERAPEUTICS,LLC
9.14.1. Overview
9.14.2. JDS THERAPEUTICS, LLC : Product Portfolio
9.14.3. Corporate Summary
9.14.4. JDS THERAPEUTICS, LLC: SWOT Analysis
9.15. NEUROCRINE BIOSCIENCES, INC.
9.15.1. Overview
9.15.2. NEUROCRINE BIOSCIENCES, INC.: Product Portfolio
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. NEROCRINE BIOSCIENCES, INC.: SWOT Analysis
9.16. Novartis International AG
9.16.1. Overview
9.16.2. Novartis International AG: Product Portfolio
9.16.3. Financials
9.16.3.1. Financial Summary
9.16.4. Novartis International AG: SWOT Analysis
9.17. NOVEN Pharmaceuticals, Inc.
9.17.1. Overview
9.17.2. Parent Company: Hisamitsu Pharmaceutical Co., Inc.: Overview
9.17.3. Hisamitsu Pharmaceutical Co., Inc.: Product Portfolio
9.17.4. Financials
9.17.4.1. Financial Summary
9.17.5. NOVEN Pharmaceuticals, Inc.: SWOT Analysis
9.18. Novo Nordisk
9.18.1. Overview
9.18.2. Novo Nordisk: Product Portfolio
9.18.3. Financials
9.18.3.1 Financial Summary
9.18.4. Novo Nordisk: SWOT Analysis
9.19. Pfizer Inc.
9.19.1. Overview
9.19.2. Pfizer Inc.: Product Portfolio
9.19.3. Financials
9.19.3.1. Financial Summary
9.19.4. Pfizer Inc.: SWOT Analysis
9.20. Radius Health Inc.
9.20.1. Overview
9.20.2. Radius Health Inc.: Product Portfolio
9.20.3. Financials
9.20.3.1. Financial Summary
9.20.4. Radius Health Inc.: SWOT Analysis
9.21. Teva Pharmaceuticals Industries Limited
9.21.1. Overview
9.21.2. Teva Pharmaceuticals Industries Limited: Product Portfolio
9.21.3. Financials
9.21.3.1. Financial Summary
9.21.4. Teva Pharmaceuticals Industries Limited: SWOT Analysis
9.22. TherapeuticsMD, Inc.
9.22.1. Overview
9.22.2. TherapeuticsMD, Inc.: Product Portfolio
9.22.3. Financials
9.22.3.1. Financial Summary
9.22.4. TherapeuticsMD, Inc.: SWOT Analysis
9.23. VALEANT Pharmaceuticals International Inc.
9.23.1. Overview
9.23.2. VALEANT Pharmaceuticals International Inc.: Product Portfolio
9.23.3. Financials
9.23.3.1. Financial Summary
9.23.4. Valeant Pharmaceuticals International Inc.: SWOT Analysis
9.24. VERTICAL PHARMACEUTICALS, LLC
9.24.1. Overview
9.24.2. Parent Company: Osmotica Pharmaceuticals: Overview
9.24.3. VERTICAL PHARMACEUTICALS, LLC: Product Portfolio
9.24.4. Corporate Summary
9.24.5. VERTICAL PHARMACEUTICALS, LLC: SWOT Analysis
9.25. Veru HEALTHCARE
9.25.1. Overview
9.25.2. Veru HEALTHCARE: Product Portfolio
9.25.3. Financials
9.25.3.1. Financial Summary
9.25.4. Veru HEALTHCARE: SWOT Analysis
List of Tables
1 Life Expectancy of Women in Different Countries
2 Global Women’s Health Market (2016 & 2023)
3 Partnership/Collaboration/Joint Ventures/Licensing Agreements
4 Regulatory Approvals
5 Mergers & Acquisitions
6 Business Expansion
7 Product Acquisitions
8 Product Launches
9 Others
10 Regulatory Scenario Across The World
11 Patent Landscape
12 Sales of Drugs for the treatment of menopause ($Million)
13 Sales of Drugs for the Treatment of Hot Flashes ($Million)
14 Drugs: Approval and Patents
15 Pharmaceutical Pipeline
16 Estimated life expectancy in years in 1960 vs. 2016
17 Overview: Abbott Laboratories
18 Overview: Agile THERAPEUTICS
19 Overview: Allergan plc.
20 Overview: Amgen Inc.
21 Overview: AstraZeneca PLC
22 Overview: Bayer AG
23 Overview: Eli Lilly and Company
24 Overview: Enteris BIOPHARMA, Inc
25 Overview: Evestra, Inc
26 Overview: FERRING PHARMACEUTICALS
27 Overview: GEDEON RICHTER PLC
28 Overview: GlaxoSmithKline Plc
29 Overview: HRA Pharma
30 Overview: JDS THERAPEUTICS, LLC
31 Overview: NEUROCRINE BIOSCIENCES, INC.
32 Overview: Novartis AG
33 Overview: NOVEN Pharmaceuticals, Inc
34 Overview: Hisamitsu Pharmaceutical Co.,
35 Overview: NOVO NORDISK
36 Overview: Pfizer Inc.
37 Overview: Radius Health Inc.
38 Overview: Teva Pharmaceuticals Industries Limited
39 Overview: TherapeuticsMD, Inc.
40 Overview: VALEANT Pharmaceuticals International Inc.
41 Overview: VERTICAL PHARMACEUTICALS, LLC
42 Overview: Veru HEALTHCARE
List of Figures
1 Some of The Issues Related to Women’s Health
2 Market Dynamics: Drivers & Restraints
3 Global Women’s Health Market Value, 2016-2023 ($Million)
4 Global Women's Health Market, 2016-2023 ($Million), by Application
5 Global Women’s Health Market, by Application, 2016
6 Global Women’s Health Market, by Application, 2023
7 Global Women’s Contraceptive Market by Type, 2016
8 Global Women’s Contraceptive Market Type, 2023
9 Global Conventional Women’s Contraceptive Market, by Product Type, 2016
10 Global Conventional Women’s Contraceptive Market, by Product Type, 2023
11 Global Women's Health Market Value by Geography, 2016 & 2023 ($Million)
12 Global Women's Health Market, by Geography, 2016
13 Global Women's Health Market, by Geography, 2023
14 Global Women’s Health Market Segmentation
15 Research Methodology
16 Data Triangulation
17 Top-Down Approach (Segmental Analysis)
18 Bottom-Up Approach (Segmental Analysis)
19 Assumptions and Limitations
20 Human Female Reproductive System
21 Market Dynamics: Drivers, Challenges & Opportunities
22 Share of Key Developments & Strategies
23 Market Share of Various Companies, 2016
24 Global Women’s Health Market, by Application
25 Global Women’s Health Market, by Application, 2016-2023 ($Million)
26 Reproductive Health of Women
27 Global Women’s Contraception Market by Type, 2016-2023 ($Million)
28 Global Conventional Contraceptive Market, by Geography 2016-2023 ($Million)
29 Global Emergency Contraceptive Market, by Geography 2016-2023 ($Million)
30 Method of Contraception And Effectiveness
31 Types of Intra Uterine Devices
32 Global Conventional Contraceptives Market by Product Type, 2016-2023 ($Million)
33 Global Oral Contraceptive Market, 2016-2023 ($Million)
34 Global Oral Contraceptive Market, by Product Type, 2016-2023 ($Million)
35 Global Oral Contraceptive Market, by Geography, 2016-2023 ($Million)
36 Global IUDs Market, by Geography, 2016-2023 ($Million)
37 Global Female Condom, Diaphragm & Sponge Market, by Geography, 2016-2023 ($Million)
38 Global Contraceptive Implants Market, by Geography, 2016-2023 ($Million)
39 Global Vaginal Rings Market, by Geography, 2016-2023 ($Million)
40 Global Others Contraceptive Market, by Geography, 2016-2023 ($Million)
41 Drugs for Treatment of Post Menopausal Health
42 Number of women with menopause- 1998 (estimated) Vs 2025 (Projected)
43 Global Menopausal Hot Flash Treatment Market, by Drug Class 2016-2023 ($Million)
44 Global Menopausal Hot Flash Treatment Market, by Geography 2016-2023 ($Million)
45 The U.S. Menopausal Hot Flash Market, 2016-2023 ($Million)
46 Canada Menopausal Hot Flash Market, 2016-2023 ($Million)
47 The U.K. Menopausal Hot Flash Market, 2016-2023 ($Million)
48 Germany Menopausal Hot Flash Market, 2016-2023 ($Million)
49 France Menopausal Hot Flash Market, 2016-2023 ($Million)
50 Rest of Europe Menopausal Hot Flash Market, 2016-2023 ($Million)
51 Australia Menopausal Hot Flash Market, 2016-2023 ($Million)
52 Japan Menopausal Hot Flash Market, 2016-2023 ($Million)
53 India Menopausal Hot Flash Market, 2016-2023 ($Million)
54 China Menopausal Hot Flash Market, 2016-2023 ($Million)
55 Rest of Asia Pacific Menopausal Hot Flash Market, 2016-2023 ($Million)
56 Latin America Menopausal Hot Flash Market, 2016-2023 ($Million)
57 MENA Region Menopausal Hot Flash Market, 2016-2023 ($Million)
58 Treatment of Post Menopausal Osteoporosis
59 Global Post Menopausal Market, by Product 2016-2023 ($Million)
60 Types of Urological Disorders
61 Population Affected by Urinary Incontinence
62 Ratio of occurrence of UTI in women vs men
63 Global Urinary Tract Infection Market, 2016-2023 ($Million)
64 Global Urinary Tract Infection Market, by Geography 2016-2023 ($Million)
65 The U.S. UTI Market, 2016-2023 ($Million)
66 Canada UTI Market, 2016-2023 ($Million)
67 The U.K. UTI Market, 2016-2023 ($Million)
68 Germany UTI Market, 2016-2023 ($Million)
69 France UTI Market, 2016-2023 ($Million)
70 Italy UTI Market, 2016-2023 ($Million)
71 Spain UTI Market, 2016-2023 ($Million)
72 Rest of Europe UTI Market, 2016-2023 ($Million)
73 Australia UTI Market, 2016-2023 ($Million)
74 Japan UTI Market, 2016-2023 ($Million)
75 India UTI Market, 2016-2023 ($Million)
76 China UTI Market, 2016-2023 ($Million)
77 Rest of Asia Pacific UTI Market, 2016-2023 ($Million)
78 Brazil UTI Market, 2016-2023 ($Million)
79 Mexico UTI Market, 2016-2023 ($Million)
80 Rest of Latin America UTI Market, 2016-2023 ($Million)
81 Classification of Products
82 Intra Uterine Devices (IUD)
83 Types of IUDs
84 IUDs By Year of FDA Approval
85 Drugs used for the treatment of female health
86 Global Women's Health Market, By Region
87 Global Women’s Health Market, by Region 2016-2023 ($Million)
88 Women’s Health Market, North America 2017-2023 ($Million)
89 North American Women’s Health Market, by Application 2017-2023 ($Million)
90 The U.S. Women’s Health Market, 2016-2023 ($Million)
91 The U.S. Women’s Health Market, by Application 2016-2023 ($Million)
92 The Canada Women’s Health Market, 2016-2023 ($Million)
93 Canada Women’s Health Market, by Application 2016-2023 ($Million)
94 Women’s Health Market Europe, 2017-2023 ($Million)
95 European Women’s Health Market, by Application 2017-2023 ($Million)
96 The U.K. Women’s Health Market, 2016-2023 ($Million)
97 The U.K. Women’s Health Market, by Application 2016-2023 ($Million)
98 Germany Women’s Health Market, 2016-2023 ($Million)
99 Germany Women’s Health Market, by Application 2016-2023 ($Million)
100 France Women’s Health Market, 2016-2023 ($Million)
101 France Women’s Health Market, by Application 2016-2023 ($Million)
102 Italy Women’s Health Market, 2016-2023 ($Million)
103 Italy Women’s Health Market, by Application 2016-2023 ($Million)
104 Spain Women’s Health Market, 2016-2023 ($Million)
105 Spain Women’s Health Market, 2016-2023 ($Million)
106 Rest of Europe Women’s Health Market, 2016-2023 ($Million)
107 Rest of Europe Women’s Health Market, 2016-2023 ($Million)
108 Women’s Health Market, Asia Pacific 2016-2023 ($Million)
109 Asia Pacific Women’s Health Market, by Application 2017-2023 ($Million)
110 Japan Women’s Health Market, 2016-2023 ($Million)
111 Japan Women’s Health Market, by Application 2016-2023 ($Million)
112 Australia Women’s Health Market, 2016-2023 ($Million)
113 Australia Women’s Health Market, by Application 2016-2023 ($Million)
114 China Women’s Health Market, 2016-2023 ($Million)
115 China Women’s Health Market, by Application 2016-2023 ($Million)
116 India Women’s Health Market, 2016-2023 ($Million)
117 India Women’s Health Market, by Application 2016-2023 ($Million)
118 Rest of Asia Pacific Women’s Health Market, 2016-2023 ($Million)
119 Rest of Asia Pacific Women’s Health Market, by Application 2016-2023 ($Million)
120 Women’s Health Market, Latin America 2017-2023 ($Million)
121 Latin American Women’s Health Market, by Application 2017-2023 ($Million)
122 Mexico Women’s Health Market, 2016-2023 ($Million)
123 Mexico Women’s Health Market, 2016-2023 ($Million)
124 Brazil Women’s Health Market, 2016-2023 ($Million)
125 Brazil Women’s Health Market, by Application 2016-2023 ($Million)
126 Rest of Latin America Women’s Health Market, 2016-2023 ($Million)
127 Rest of Latin America Women’s Health Market, by Application 2016-2023 ($Million)
128 Women’s Health Market, Rest of the World 2017-2023 ($Million)
129 Rest of the World Women’s Health Market, by Application 2017-2023 ($Million)
130 Abbott Laboratories: Product Portfolio
131 Abbott Laboratories : Overall Financials (2014-2016)
132 Abbott Laboratories: Net Revenue By Business Segments (2014-2016)
133 Abbott Laboratories: Net Revenue By Geography (2014-2016)
134 Abbott Laboratories: SWOT Analysis
135 Agile THERAPEUTICS: Product Portfolio
136 Agile THERAPEUTICS: Overall Financials (2014-2016)
137 Agile THERAPEUTICS: Research and Development Expenses (2014-2016)
138 Agile THERAPEUTICS: SWOT Analysis
139 Allergan plc: Product portfolio
140 Allergan plc: Overall Financials (2014-2016)
141 Allergan plc: Net Revenue by Business Sub-Segment of The U.S. Specialized Therapeutics (2015-2016)
142 Allergan plc: Net Revenue by Business Segment (2014)
143 Allergan plc: Net Revenue By Business Segment (2015-2016)
144 Allergan plc: SWOT Analysis
145 Amgen Inc.: Product Portfolio
146 Amgen Inc.: Overall Financials (2014-2016)
147 Amgen: Net Revenue by Geography (2014-2016)
148 Amgen Inc: SWOT Analysis
149 AstraZeneca PLC: Product Portfolio
150 AstraZeneca PLC: Net Revenue By Business Segments (2014-2016)
151 AstraZeneca plc: Revenue By Different Geographies (2014-2016)
152 AstraZeneca PLC: SWOT Analysis
153 Bayer AG: Product Portfolio
154 Bayer AG : Overall Financials, 2014-2016
155 Bayer AG: Net Revenue by Business Segments (2014-2016)
156 Bayer AG: Net Revenue By Geography (2014-2016)
157 Bayer AG: SWOT Analysis
158 Eli Lilly and Company: Product Portfolio
159 Eli Lilly and Company: Overall Financials (2014-2016)
160 Eli Lilly and Company: Net Sales By Business Segment (2014-2016)
161 Eli Lilly and Company: Net Sales By Geography (2014-2016)
162 Eli Lilly and Company: SWOT Analysis
163 Enteris BIOPHARMA, Inc: Product Portfolio
164 Enteris BIOPHARMA ,Inc: SWOT Analysis
165 Evestra, Inc: Product portfolio
166 Evestra, Inc: SWOT Analysis
167 FERRING PHARMACEUTICALS: Product Portfolio
168 FERRING PHARMACEUTICALS: SWOT Analysis
169 GEDEON RICHTER PLC: Product Portfolio
170 GEDEON RICHTER PLC,: Overall Financials(2014-2016)
171 GEDEON RICHTER PLC: Net Revenue by Business Segments (2014-2016)
172 GEDEON RICHTER PLC: Net Revenue By Geography (2016)
173 GEDEON RICHTER PLC: Net Revenue By Geography (2014-2015)
174 ON RICHTER PLC: Net Revenue By Geography (2014-2016)
175 GEDEON RICHTER PLC: NET REVENUE WOMEN’S HEALTHCARE(2014-2016)
176 GEDEON RICHTER PLC: SWOT Analysis
177 GlaxoSmithKline Plc: Product Portfolio
178 GlaxoSmithKline Plc.: Overall Financials (2013-2016)
179 GlaxoSmithKline: Net Revenue By Business Segments (2014-2016)
180 GlaxoSmithKline: Net Revenue By Geography
181 GlaxoSmithKline Plc: Net Revenue by Geography (2016)
182 GlaxoSmithKline Plc: SWOT Analysis
183 HERA Pharma: Product portfolio
184 HERA Pharm :SWOT Analysis
185 JDS THERAPEUTICS, LLC: Product Portfolio
186 JDS THERAPEUTICS ,LLC :SWOT Analysis
187 NEUROCRINE BIOSCIENCES, INC.: Product Portfolio
188 NEUROCRINE BIOSCIENCES, INC: Overall Financials (2014-2016)
189 NEUROCRINE BIOSCIENCES, INC.: R&D Expenses by Segment (2014-2016)
190 NEUROCRINE BIOSCIENCES, INC.: R&D Expenses of External Development by Product(2014-2016)
191 NEUROCRINE BIOSCIENCES, INC: SWOT Analysis
192 Novartis AG: Product Portfolio
193 Novartis: Overall Financials (2014-2016)
194 Novartis: Net Revenue by Business Segments (2013-2014)
195 Novartis: Net Revenue by Business Segments (2015-2016)
196 Novartis: Net Revenue by Geography (2016)
197 Novartis: Net Revenue by Geography (2014-2015)
198 Figure: Novartis AG: SWOT Analysis
199 NOVEN Pharmaceuticals, Inc: Product Portfolio
200 Hisamitsu Pharmaceuticals Co. Inc.: Overall Financials
201 Hisamitsu pharmaceuticals Co. Inc.: Net sales by Business segment (2014-2016)
202 NOVEN Pharmaceuticals, Inc: Overall Financials (2014-2016)
203 Hisamitsu pharmaceuticals Co. Inc.: Net sales by Geographical Segment (2014-2016)
204 NOVEN Pharmaceuticals: SWOT Analysis
205 NOVO NORDISK: Product Portfolio
206 Novo Nordisk: Overall Financials, 2014-2016
207 Novo Nordisk: Net Revenue By Business Segment (2014-2016)
208 Novo Nordisk, Net Revenue by Geography (2014-2016)
209 Novo Nordisk: SWOT Analysis
210 Pfizer Inc.: Product Portfolio
211 Pfizer Inc.: Overall Financials(2014-2016)
212 Pfizer: Net Revenue by Geography (2014-2016)
213 Pfizer: Net Revenue by Business Segments (2014-2016)
214 Pfizer Inc.: SWOT Analysis
215 Radius Health Inc.: Product Portfolio
216 Radius Health Inc: Overall Financials (2014-2016)
217 Radius Health Inc.: Research and Development Expenses BY Product (2014-2016)
218 Radius Health Inc.: SWOT Analysis
219 Teva Pharmaceutical Industries Limited: Product Portfolio
220 Teva Pharmaceuticals Industries Limited: Overall Financials (2014-2016)
221 Teva Pharmaceutical Industries: Net Revenue by Geography (2014-2016)
222 Teva Pharmaceutical Industries Limited: Net Revenue by Sub-Segments (2014-2016)
223 Teva Pharmaceutical Industries: Net Revenue by Business Segment (2014-2016)
224 Teva Pharmaceutical Industries Ltd.: SWOT Analysis
225 TherapeuticsMD, Inc.: Product Portfolio
226 TherapeuticsMD: Overall Financials (2014-2016)
227 TherapeuticsMD, Inc. : SWOT Analysis
228 VALEANT Pharmaceuticals International Inc.: Product Portfolio
229 VALEANT Pharmaceuticals International Inc: Overall Financials (2014-2016)
230 VALEANT Pharmaceuticals International Inc: Net Revenue by Business Segment (2014-2016)
231 VALEANT Pharmaceuticals International Inc: Net Revenue by Region (2014-2016)
232 Valeant Pharmaceuticals : SWOT Analysis
233 VERTICAL PHARMACEUTICALS, LLC: Product Portfolio
234 VERTICAL PHARMACEUTICALS, LLC: SWOT Analysis
235 Veru HEALTHCARE: Product Portfolio
236 Veru HEALTHCARE: Overall Financials (2014-2016)
237 Veru HELTHCARE:Net revenue by Geography (2014)
238 Veru HEALTHCARE: NET REVENUE BY GEOGRAPHY 2015-2016)
239 Veru HEALTHCARE: SWOT Analysis
The concern regarding women’s health is pivotal for the overall well-being of the society. Yet, it is an issue that has always been neglected due to several sociocultural factors prevailing in the society. The advent of the 21st century witnessed a sharp rise in the level of awareness among people regarding women’s health, the focus is now on better education and accessibility of services in different countries. As estimated in April 2017, the total world population accounted for approximately 7.5 billion out of which women accounted for 49.6%. Though it has been observed that women live longer than men, a longer life does not indicate a healthy life. Women undergo a lot of hormonal, emotional and physiological changes during their lifetime. The focus is now on providing better education and accessibility to services in different countries across the globe.
The purpose of the study is to gain a holistic view of the women’s health market in the terms of various factors influencing it, such as recent trends, technological advancements, and the regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the women’s health market. The market has been segmented into ‘Application’, ‘product’, and ‘geographical regions’.
The global women’s health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The rising geriatric population among women leading to higher incidence rate of menopause and related diseases is the major factor driving the growth of the market. With women becoming more career oriented and marriages being delayed, the infertility rates have been increasing. Other factors affecting women health include stress and changing lifestyle.
The global women’s health market can be segmented on the basis of applications, such as reproductive, menopausal, urological & others. The major contributor to the market growth, in 2016, was the contraceptives. The contraceptive market was estimated at $15.97 billion in 2016. Based on the product, the market has been segmented into drugs & devices.
North America was the major revenue contributing region, by geography, because of the rising population of elderly women and higher life expectancy leading to the increased prevalence of menopausal conditions and osteoporosis. It was estimated at $13.64 billion in 2016 & is expected to reach $17.36 billion in 2023. The region also exhibits a higher prevalence of obesity which leads to the higher prevalence of infertility. It has been observed that more menopausal symptoms were reported among the American women. The highest CAGR is expected to be of Latin America with a value of 7.1%, during the forecast period 2017-2023.
The emerging opportunities for the women’s health market are the treatment options for various conditions like PCOS, reproductive health diseases, and endometriosis, among others. The market has not witnessed innovative and breakthrough therapies in the recent years. The rising emphasis on the wellbeing of women, the increased awareness about contraceptives and pharmaceuticals and use of natural hormonal preparations are other factors which will guide the growth of the market.
The report provides in-depth SWOT analysis of different key players of the market, supported by a financial summary of each of the players. Some of the key players are Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE.
North America
Europe
Asia Pacific
Rest of the World
Global Women’s Health Market report, Women’s Health Market research report, Women’s Health Market report, Women’s Health Market research, Women’s Health Market trends, Women’s Health Market forecast, Women’s Health Market size, Women’s Health Market share, Women’s Health Market analysis, Global Women’s Contraceptive Market, Global Oral Contraceptive Market, Global Emergency Contraceptive Market, Global Conventional Contraceptive Market.
The concern regarding women's health is pivotal for the overall well-being of the society. Yet, it is an issue that has always been neglected due to several socio-cultural factors prevailing in the society. The focus is now on providing better education and accessibility to services in different countries across the globe. The overall health market is dependent on factors, such as percentage of young and older women, demographic and social factors and the public outlook towards contraception and family planning. The life expectancy for females was estimated to be 73.8 years in 2015. As of April 2017, women accounted for 49.6% of the total world population. The world population is aging faster and women accounted for 54% of the population belonging to the age group of 60 years or over, in 2015. Though it has been observed that women live longer than men, a longer life does not indicate a healthy life. Women undergo a lot of hormonal, emotional, and physiological changes during their lifetime.
The rising geriatric population among women leading to a higher incidence rate of menopause and related diseases is the major factor driving the market. The cases of infertility are also increasing with women coping with the rising stress from jobs and consequential delay in pregnancy. Other factors affecting women's health include stress and changing lifestyle.
BIS Research Report: link
According to a new market intelligence report by BIS Research, titled "Global Women's Health Market- Analysis and Forecast, 2017-2023", the global women's health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The increasing population of elderly women is the main factor driving the growth of this market. Apart from this, the rising awareness about the long-neglected topic of women's health is another factor.
The market has not witnessed any breakthrough technologies or emerging treatments in the last decade, the lack of innovation being the main restraint for the market. Thus, the market presents the opportunity for innovation through investment in the pipeline of drugs. The rising emphasis on the wellbeing of women, increased awareness about contraceptives and pharmaceuticals and use of natural hormonal preparations are other factors which will guide the growth of the market.
According to the analyst at BIS Research, "The women health remains to be a neglected topic in the developed as well as the developing nations, along with the prevalent discrimination on the basis of gender. In the developing countries, especially, women lack basic education, health facilities, and face sex-based disparities. Women health is gaining attention on the international front for quite some time now. As women age, different physiological and emotional changes are said to occur. The hormones in the female body play an important part in these transformations. "
Research Highlights:
• Major contributor towards the market in 2016 was the contraceptives segment. The market for contraceptives was estimated at $15.97 billion in 2016.
• Market for the global women's health was estimated at $30.88 billion in 2016 with the highest CAGR of 5.5%
• Among the conventional contraceptives, oral contraceptives were found to be the largest revenue generating segment. The market for oral contraceptives was estimated at $6.39 billion in 2016.
• The market for the treatment of menopausal hot flash syndrome was estimated at $4.10 billion in 2016. The major contributing product segment was estrogens with a value of $2.25 billion in 2016.
• North America was the major contributor to the market in 2016. The market for North America is expected to reach $17.36 billion by 2023. This is mainly due to the rising population of elderly women & increasing delayed marriages.
Source: BIS Research Analysis
Request for Sample Report: link
This market intelligence report provides a multidimensional view of the global women's health market in terms of market size and growth potential. This research report aims at answering various aspects of the global women's health market with the help of the key factors driving the market, the threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global women's health market and assesses the factors governing the same.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with recent market activities, such as product launches, regulatory clearance, certifications, partnerships, collaborations, business expansions, and mergers and acquisitions etc. The research report provides a comprehensive analysis of product sales, manufacturers and trend analysis by the segments and demand by the geographical regions. The report also presents the pipeline of therapeutic candidates which are undergoing various stages of development & may be available in the future..
The report profiles 26 companies including many key players, such as Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE, among others.

Key questions answered in the report:
• What are the major market drivers, challenges, and opportunities in the global women’s health market?
• How did the women’s health market evolve and what is its scope in the future?
• What is the market share of the leading segments and sub-segments of the global women’s health market in 2016 and 2023?
• How will each segment of the global women’s health market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016- 2023?
• What are the key developmental strategies which are being implemented by the key players to stand out in this market?
• How has the market been segmented on the basis of application?
• What are the treatment options for postmenopausal symptoms?
• What is the estimated value for the menopausal hot flash market?
• What is the value of different types of contraceptives in the market?
• What will be the value of hormonal contraceptives segment by 2023?
• Which geographical location will contribute to the highest sales of the products?
Abbott Laboratories
Agile THERAPEUTICS
Allergan plc.
AstraZeneca PLC
Bayer AG
Eli Lilly and Company
Enteris BIOPHARMA, Inc
Evestra, Inc
FERRING PHARMACEUTICALS
GEDEON RICHTER PLC
GlaxoSmithKline Plc
HRA Pharma
JDS THERAPEUTICS,LLC
NEUROCRINE BIOSCIENCES, INC.
Novartis International AG
NOVEN Pharmaceuticals, Inc.
Global Women’s Health Market to reach $42.12 Billion by 2023, Reports BIS Research